| abstract |
A pyrazole derivative capable of expressing an excellent human sodium/glucose cotransporter (SGLT) inhibiting activity, which pyrazole derivative is useful as a preventive, progress inhibitor or therapeutic agent for diseases (diabetes mellitus, after-meal hyperglycemia, impaired glucose tolerance, diabetic complications, etc.) attributed to excess introjection of at least one carbohydrate selected from among glucose, fructose and mannose. The pyrazole derivative is represented by the general formula: (I) [R1 is H, a substituted or unsubstituted C1-6 alkyl, etc.; one of Q and T is a group selected from among: and while the other is -Z-Ar (wherein Z is -O-, -S-, etc. and Ar is a substituted or unsubstituted C6-10 aryl, etc.), etc.; and R is a substituted or unsubstituted C3-8 cycloalkyl, a substituted or unsubstituted C6-10 aryl, etc.]. There are further provided a pharmacologically acceptable salt of the pyrazole derivative, a prodrug thereof and a drug composition containing them. There are still further provided a medical use thereof and a production intermediate therefor. |